Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of BAT2306 and Cosentyx in moderate to severe plaque psoriasis
jRCT2051220123Phase 3Active, not recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing BAT2306 continuous treatment, Cosentyx continuous treatment and Cosentyx to BAT2306 switch (3 arms). Started Feb 2023; status: active, not recruiting.
02
Drugs
BAT2306secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2051220123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220123.